Dagmar Schlenzig

Dagmar Schlenzig


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Neurochemistry International
Verified
Journal Article
Closed access
AAAlvard Antonyan
Alvard Antonyan
DSDagmar Schlenzig
Dagmar Schlenzig
SSStephan Schilling
Stephan Schilling
MNMarcel Naumann
Marcel Naumann
AAArmen Andreasyan
Armen Andreasyan
HDHans-Ulrich Demuth
Hans-Ulrich Demuth

19 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CBCharles Bayly-Jones
Charles Bayly-Jones
CLChristopher J. Lupton
Christopher J. Lupton
CFClaudia Fritz
Claudia Fritz
HVHariprasad Venugopal
Hariprasad Venugopal
DRDaniel Ramsbeck
Daniel Ramsbeck
James C WhisstockJames C Whisstock
James C Whisstock
The zinc-dependent metalloprotease meprin α is predominantly expressed in the brush border membrane of proximal tubules in the kidney and enterocytes in the small intestine and colon. In normal tissue homeostasis meprin α performs key roles in inflammation, immunity, and extracellular matrix remodelling. Dysregulated meprin α is associated with acute kidney injury, sepsis, urinary tract infection, metastatic colorectal carcinoma, and inflammatory bowel disease. Accordingly, meprin α is the target of drug discovery programs. In contrast to meprin β, meprin α is secreted into the extracellular space, whereupon it oligomerises to form giant assemblies and is the largest extracellular protease identified to date (~6 MDa). Here, using cryo-electron microscopy, we determine the high-resolution structure of the zymogen and mature form of meprin α, as well as the structure of the active form in complex with a prototype small molecule inhibitor and human fetuin-B. Our data reveal that meprin α forms a giant, flexible, left-handed helical assembly of roughly 22 nm in diameter. We find that oligomerisation improves proteolytic and thermal stability but does not impact substrate specificity or enzymatic activity. Furthermore, structural comparison with meprin β reveal unique features of the active site of meprin α, and helical assembly more broadly.

16 July 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
KTKathrin Tan
Kathrin Tan
CJChristian Jäger
Christian Jäger
DSDagmar Schlenzig
Dagmar Schlenzig
Stephan SchillingStephan Schilling
Stephan Schilling
MBMirko Buchholz
Mirko Buchholz
DRDaniel Ramsbeck
Daniel Ramsbeck

Verified
Journal Article
Open access
PDF file
MLMiriam Linnert
Miriam Linnert
CFClaudia Fritz
Claudia Fritz
CJChristian Jäger
Christian Jäger
DSDagmar Schlenzig
Dagmar Schlenzig
DRDaniel Ramsbeck
Daniel Ramsbeck
Stephan SchillingStephan Schilling
Stephan Schilling
The astacin protease Meprin β represents an emerging target for drug development due to its potential involvement in disorders such as acute and chronic kidney injury and fibrosis. Here, we elaborate on the structural basis of inhibition by a specific Meprin β inhibitor. Our analysis of the crystal structure suggests different binding modes of the inhibitor to the active site. This flexibility is caused, at least in part, by movement of the C-terminal region of the protease domain (CTD). The CTD movement narrows the active site cleft upon inhibitor binding. Compared with other astacin proteases, among these the highly homologous isoenzyme Meprin α, differences in the subsites account for the unique selectivity of the inhibitor. Although the inhibitor shows substantial flexibility in orientation within the active site, the structural data as well as binding analyses, including molecular dynamics simulations, support a contribution of electrostatic interactions, presumably by arginine residues, to binding and specificity. Collectively, the results presented here and previously support an induced fit and substantial movement of the CTD upon ligand binding and, possibly, during catalysis. To the best of our knowledge, we here present the first structure of a Meprin β holoenzyme containing a zinc ion and a specific inhibitor bound to the active site. The structural data will guide rational drug design and the discovery of highly potent Meprin inhibitors.

20 January 2023 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
KTKathrin Tan
Kathrin Tan
CJChristian Jäger
Christian Jäger
SGStefanie Geissler
Stefanie Geissler
DSDagmar Schlenzig
Dagmar Schlenzig
MBMirko Buchholz
Mirko Buchholz
DRDaniel Ramsbeck
Daniel Ramsbeck
Targeting metalloproteinases has been in the focus of drug design for a long time. However, meprin α and β emerged as potential drug targets just recently and are linked to several diseases with different pathological background. Nevertheless, the validation of meprins as suitable drug targets still requires highly potent and selective inhibitors as chemical probes to elucidate their role in pathophysiology. Albeit highly selective inhibitors of meprin β have already been reported, only inhibitors of meprin α with modest activity or selectivity are known. Starting from recently reported heteroaromatic scaffolds, the aim of this study was the optimisation of meprin α and/or meprin β inhibition while keeping the favourable off-target inhibition profile over other metalloproteases. We report potent pan-meprin inhibitors as well as highly active inhibitors of meprin α with superior selectivity over meprin β. The latter are suitable to serve as chemical probes and enable further target validation.

8 June 2017 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
CSClaudia Spahn
Claudia Spahn
MWMichael Wermann
Michael Wermann
RERico Eichentopf
Rico Eichentopf
GHGerd Hause
Gerd Hause
DSDagmar Schlenzig
Dagmar Schlenzig
SSStephan Schilling
Stephan Schilling